Related Experiment Video
Updated: May 4, 2026
A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids
Published on: October 13, 2019
[Bezafibrate in an infant with congenital generalized lipodystrophy and severe hypertriglyceridemia]
Insights
Congenital generalized lipodystrophy (CGL) in infants with severe hypertriglyceridemia can be managed with bezafibrate. This treatment effectively controlled triglycerides but did not prevent hepatic steatosis.
Area of Science:
- Biochemistry
- Pediatrics
- Endocrinology
Background:
- Congenital generalized lipodystrophy (CGL) presents a significant metabolic risk in infants, particularly with severe hypertriglyceridemia.
- Early-onset metabolic complications necessitate effective therapeutic interventions.
Observation:
- A case study of an infant diagnosed with CGL type 2 exhibiting hypertriglyceridemia (1,360 mg/dL).
- The infant was treated with bezafibrate (30-60 mg/day) from 11 months to 5.5 years of age.
Findings:
- Bezafibrate therapy achieved a nadir triglyceride level of 55 mg/dL, normalizing lipid profiles.
- While preventing diabetes mellitus, bezafibrate did not avert the development of hepatic steatosis.
- The treatment demonstrated efficacy in managing hypertriglyceridemia and cholesterol levels without severe adverse effects.
Implications:
- Bezafibrate is a viable hypolipidemic therapy for CGL, effectively controlling triglyceride levels in young children.
- Long-term monitoring for hepatic steatosis is crucial even with effective lipid management in CGL patients.
- Further research into comprehensive CGL management strategies is warranted to address all metabolic sequelae.
Abstract:
Congenital generalized lipodystrophy (CGL) with severe hypertriglyceridemia in a children less than 1 year of age is associated with worse metabolic risk. We used data from patient records, as well as extensive literature research to write the manuscript. We report the case of an infant with typical phenotype of CGL and hypertriglyceridemia of 1,360 mg/dL who was treated with bezafibrate at a dose of 30 to 60 mg/day from age 11 months to 5.5 years old, with a measurement of nadir of triglycerides of 55 mg/dL. Clinical evolution and clinical laboratory tests before and after bezafibrate were carried out over 5 years and 6 months. Phenotype was classified as CGL type 2. Despite the efficient control of hypertriglyceridemia and absence of development of diabetes mellitus, the use of bezafibrate did not prevent the onset of hepatic steatosis during evolution. Hypolipidemic therapy with bezafibrate proved effective in maintaining the levels of triglycerides, cholesterol and its fractions at normal levels, and its use was not correlated with severe side effects during the described period.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:06Lipid Digestion
01:25Lipid Catabolism
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...